AACR 2023: CRB-601, an αvβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment
CRB-601, an integrin avβ8 blocking antibody entering Phase I: pre-clinical and translational biomarkers for indication selection
CRB-601, a selective integrin αvβ8-blocking antibody, prevents TGFβ activation, promotes immune cell remodeling, and exhibits potent antitumor activity
CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models
CRB-913: A Novel Oral Cannabinoid Receptor-1 (CB1R) Inverse Agonist Enhances Tirzepatide and Semaglutide Efficacy in a Diet Induced Obesity Mouse Model
CRB-913: Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutide in the diet-induced obesity mouse model
58th European Association for the Study of Diabetes (EASD) presentation on CRB-913 (CB1 Inverse Agonist)
Phase 1 Dose-Escalation of SYS6002 (CRB-701) A next-generation Nectin-4 Targeting Antibody Drug Conjugate (ADC) Poster
